Recent studies and surveys highlight the multifaceted impacts of GLP-1 receptor agonists, including semaglutide and tirzepatide, commonly known under brand names such as Ozempic and Wegovy. A cohort study found that these drugs are associated with a reduced risk of dementia, stroke, and all-cause mortality among adults with type 2 diabetes and obesity. Research also suggests that significant weight loss can be achieved without continuous use of these medications. Additionally, a survey indicates that 50-60% of users report changes in their sex and dating lives. Medical professionals have emphasized important considerations for patients before using these drugs. There is also emerging evidence that micro-dosing GLP-1 receptor agonists may provide meaningful benefits while minimizing side effects, as current high doses might be excessive. Furthermore, scientific investigations reveal that users of drugs like Ozempic have a notably lower likelihood of developing brain diseases. Specific effects on men have also been reported, indicating unique changes beyond weight loss.